![Doug Lowy on the moonshot, NCI's invigorated agenda](https://cdn.cancerletter.com/media/2017/01/portrait-web.jpg)
![Doug Lowy on the moonshot, NCI's invigorated agenda](https://cdn.cancerletter.com/media/2017/01/portrait-web.jpg)
Cover Story
Free
As administrations change, cancer research stands in an unusually strong position, NCI Acting Director Douglas Lowy said in an interview with The Cancer Letter.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Funding Opportunities
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- Murphy, McKay, Nodora, Ballantyne, Stupack named associate directors at UCSD Moores
- The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop